HUTCHMED (00013) rose more than 4% again, bringing its cumulative gain for the month to over 20%. At the time of writing, the stock was up 3.68% to HK$24.8, with a turnover of HK$142 million.

The company announced that the results from the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib and osimertinib for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.

Savolitinib is a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI.

Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.